Novel approach harnessing the power of the complement system to drive potent cell depletion Single-dose study shows rapid and sustained immune cell depletion in blood and tissues with a very favourable safety profile Commit Biologics’ CEO Mikkel Wandahl Pedersen to present data at PEGS Europe summit, November 11-13, 2025 in Lisbon, Portugal Aarhus, Denmark, November […]
Additional funding from new investor Korys, joining existing syndicate members Novo Holdings and Bioqube Ventures, brings total seed financing to €21.5m Funds will be used to further develop Commit’s BiCE platform and move towards drug candidate (DC) selection Eva Van Overmeire, Senior Investment Manager at Korys, also joins Commit’s Board of Directors Mikkel Wandahl Pedersen […]
Former senior vice president of antibody research at Genmab who has co-invented numerous FDA-approved therapeutic antibodies and as well as its DuoBody® bi-specific antibody platform. Brings decades of experience in developing strong pipelines of antibody-based drugs from platforms, growing scientific teams and managing partnerships with Pharma companies Appointment comes as Commit looks to progress towards […]
Highly experienced leader with demonstrated track record of antibody-based drug discovery and pipeline advancement Strengthens Commit’s leadership team after emerging from stealth with €16m seed financing Dr Pedersen will spearhead research and development of Commit’s BiCETM technology as the Company moves towards drug candidate (DC) nomination Aarhus, Denmark, 15 October 2024 – Commit Biologics (“Commit”), […]
Commit Biologics is pioneering a novel approach to activating the complement component of the immune system to treat cancer and autoimmune diseases Poster to be presented on Commit’s Bispecific Complement Engaging (BiCE™) platform Aarhus, Denmark, 10 June 2024 – Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer […]
